ofloxacin has been researched along with doripenem in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, S; Ike, Y; Okuzumi, K; Tanimoto, K; Tomita, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
| Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W | 1 |
| Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R | 1 |
| Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R | 1 |
| Inoue, K; Iwasaki, T; Takaku, K; Yamamoto, T | 1 |
| Kaniga, K; Lee, M; Redman, R; Rice, DA | 1 |
| Davies, TA; He, W; Lynch, AS; Queenan, AM | 1 |
2 review(s) available for ofloxacin and doripenem
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A case of Lemierre's syndrome in association with liver abscess without any other metastatic lesions.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Disseminated Intravascular Coagulation; Doripenem; Fusobacterium necrophorum; Humans; Lemierre Syndrome; Liver Abscess; Male; Ofloxacin | 2012 |
4 trial(s) available for ofloxacin and doripenem
| Article | Year |
|---|---|
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prospective Studies; Pyelonephritis; Urinary Tract Infections | 2009 |
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pyelonephritis; Urinary Tract Infections | 2009 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Urinary Tract Infections | 2010 |
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem; Intraabdominal Infections; Male; Meropenem; Ofloxacin; Pneumonia; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
4 other study(ies) available for ofloxacin and doripenem
| Article | Year |
|---|---|
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroquinolones; Genes, Bacterial; Humans; In Vitro Techniques; Meropenem; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Mice; Ofloxacin; Pneumonia, Ventilator-Associated; Random Allocation; Survival Analysis | 2013 |